Replies to post #29669 on Biotech Values

[walldiver]

re CA4P...

Too small of an indication is no excuse anymore. Companies can make a bundle in orphan drug indications, just look at GENZ and BMRN. It's also a way of picking off the low-hanging fruit on the way to off-label use in other indications.